Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Biocept stock
Learn how to easily invest in Biocept stock.
Biocept Inc is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 104 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Biocept
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BIOC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Biocept stock price (NASDAQ: BIOC)Use our graph to track the performance of BIOC stocks over time.
Biocept shares at a glance
|Latest market close||$2.86|
|52-week range||$2.98 - $8.38|
|50-day moving average||$3.73|
|200-day moving average||$4.03|
|Wall St. target price||$13.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.22|
Buy Biocept shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Biocept stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biocept price performance over time
|1 week (2022-01-21)||-5.30%|
|1 month (2021-12-28)||-21.86%|
|3 months (2021-10-28)||-25.13%|
|6 months (2021-07-28)||-31.58%|
|1 year (2021-01-28)||-51.53%|
|2 years (2020-01-28)||778.11%|
|3 years (2019-01-28)||35.55%|
|5 years (2017-01-27)||83.33%|
Is Biocept stock undervalued or overvalued?
Valuing Biocept stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biocept's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biocept's P/E ratio
Biocept's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biocept shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biocept's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.7 million.
The EBITDA is a measure of a Biocept's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$65.8 million|
|Operating margin TTM||5.15%|
|Gross profit TTM||$6.1 million|
|Return on assets TTM||4.47%|
|Return on equity TTM||10.1%|
|Market capitalisation||$50.9 million|
TTM: trailing 12 months
Biocept share dividends
We're not expecting Biocept to pay a dividend over the next 12 months.
Have Biocept's shares ever split?
Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Biocept share price volatility
Over the last 12 months, Biocept's shares have ranged in value from as little as $2.98 up to $8.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.4465. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus.
Biocept in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Markets are expected to remain on edge as the Fed meets in the week ahead
Frequently asked questionsWhat percentage of Biocept is owned by insiders or institutions?
Currently 0.037% of Biocept shares are held by insiders and 12.076% by institutions. How many people work for Biocept?
Latest data suggests 104 work at Biocept. When does the fiscal year end for Biocept?
Biocept's fiscal year ends in December. Where is Biocept based?
Biocept's address is: 9955 Mesa Rim Road, San Diego, CA, United States, 92121 What is Biocept's ISIN number?
Biocept's international securities identification number is: US09072V5012 What is Biocept's CUSIP number?
Biocept's Committee on Uniform Securities Identification Procedures number is: 09072V105
More guides on Finder
Cathie Wood’s ARK analysts predict Bitcoin at $1 million each by 2030
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Ask an Expert